Issue 43, 2019

A spermine-conjugated lipophilic Pt(iv) prodrug designed to eliminate cancer stem cells in ovarian cancer

Abstract

We developed a spermine-conjugated lipophilic Pt(IV) prodrug that is able to reduce the cancer stem cell population in ovarian cancer. The therapeutic effect is attributed to the hydrophobic tail and cationic spermine head group, the combination of which allows the Pt(IV) prodrug to localize in mitochondria and induce corresponding damage.

Graphical abstract: A spermine-conjugated lipophilic Pt(iv) prodrug designed to eliminate cancer stem cells in ovarian cancer

Supplementary files

Article information

Article type
Communication
Submitted
14 Mar 2019
Accepted
26 Apr 2019
First published
01 May 2019

Chem. Commun., 2019,55, 6106-6109

A spermine-conjugated lipophilic Pt(IV) prodrug designed to eliminate cancer stem cells in ovarian cancer

M. Stilgenbauer, A. M. D. S. Jayawardhana, P. Datta, Z. Yue, M. Gray, F. Nielsen, D. J. Bowers, H. Xiao and Y. Zheng, Chem. Commun., 2019, 55, 6106 DOI: 10.1039/C9CC02081K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements